Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease.
OBJECTIVE
Overexpression of elastolytic cysteine and aspartic proteases, known as cathepsins, is implicated in atherogenesis. The potential significance of imbalance in expression between cathepsins and their inhibitor cystatin C in cardiovascular disease has been highlighted by the demonstration of cystatin C deficiency in human atherosclerosis and abdominal aortic aneurysms.


RESULTS
We identified and characterized physiologically relevant polymorphisms in the promoter region of the cystatin C gene that influence cystatin C production and used these polymorphisms as a tool to examine the significance of cystatin C in coronary atherosclerosis in vivo in humans. Seven polymorphisms, all in strong-linkage disequilibrium, were identified in the cystatin C gene, of which 2 promoter polymorphisms (-82G/C and -78T/G) were functional in vitro in electromobility shift and transient transfection assays. Genotyping of 1105 individuals (237 survivors of a first myocardial infarction before age 60 and 2 independent groups comprising a total of 868 healthy individuals) revealed that the plasma cystatin C concentration was significantly lower in carriers of the mutant haplotype. Furthermore, the mutant haplotype was associated with a higher average number of stenoses per coronary artery segment in unselected postinfarction patients (N=237) undergoing routine coronary angiography.


CONCLUSIONS
These results provide human evidence for an important role of cystatin C in coronary artery disease.
Eriksson
Per
P
Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, S-171 76 Stockholm, Sweden. Per.Eriksson@medks.ki.se
Deguchi
Hiroyuki
H
Samnegård
Ann
A
Lundman
Pia
P
Boquist
Susanna
S
Tornvall
Per
P
Ericsson
Carl-Göran
CG
Bergstrand
Lott
L
Hansson
Lars-Olof
LO
Ye
Shu
S
Hamsten
Anders
A
D000483:Alleles; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D055316:Cystatin C; D015891:Cystatins / Q000096:biosynthesis / Q000097:blood / Q000235:genetics / Q000502:physiology*; D024202:Electrophoretic Mobility Shift Assay; D005091:Exons / Q000235:genetics; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000235:genetics; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic / Q000235:genetics; D012494:Sampling Studies; D013548:Sweden / Q000453:epidemiology; D014162:Transfection; D020298:U937 Cells
C525030:CST3 protein, human; D055316:Cystatin C; D015891:Cystatins